Search
Research
A Phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine given as a series of 2 infant doses and 1 toddler dose in healthy infants (NeXXstep)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
OPTIMUM: OPTimising IMmunisation Using Mixed schedulesPat Peter Susan Tom Jennifer Holt Richmond Prescott Snelling Kent PhD, DSc, FRCPath, FRCPI, FAA MBBS MRCP(UK) FRACP MBBS BMedSci PhD FRACP BMBS DTMH
Research
Adverse event reports of anaphylaxis after Comirnaty and Vaxzevria COVID-19 vaccinations, Western Australia, 22 February to 30 June 2021Within the first 4 months of the Western Australian COVID-19 immunisation programme, 49 suspected anaphylaxis cases were reported to the vaccine safety surveillance system. Twelve reports met Brighton Collaboration case definition, corresponding to rates of 15.9 and 17.7 per million doses of Vaxzevria and Comirnaty administered respectively.
Research
Plasma secretory phospholipase A2 as an early marker for late-onset sepsis in preterm infants—a pilot studyPreterm infants are particularly susceptible to bacterial late-onset sepsis (LOS). Diagnosis by blood culture and inflammatory markers have sub-optimal sensitivity and specificity and prolonged reporting times. There is an urgent need for more rapid, accurate adjunctive diagnostics in LOS to improve management and minimise antibiotic exposure.
Research
OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine scheduleCombination vaccines containing whole-cell pertussis antigens were phased out from the Australian national immunisation programme between 1997 and 1999 and replaced by the less reactogenic acellular pertussis (aP) antigens. In a large case-control study of Australian children born during the transition period, those with allergist diagnosed IgE-mediated food allergy were less likely to have received whole-cell vaccine in early infancy than matched population controls (OR: 0.77 (95% CI, 0.62 to 0.95)). We hypothesise that a single dose of whole-cell vaccine in early infancy is protective against IgE-mediated food allergy.
Research
Neonatal antigen-presenting cells are functionally more quiescent in children born under traditional compared with modern environmental conditionsOne explanation for the high burden of allergic and autoimmune diseases in industrialized countries is inappropriate immune development under modern...
Research
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 yearsIn women older than 25 years, the HPV 16/18 vaccine continues to protect against infections, cytological abnormalities, and lesions associated with HPV 16/18
Research
Children with otitis media mount a pneumococcal serotype specific serum IgG and IgA response comparable to healthy controls after pneumococcal conjugate vaccinationWe investigated the suggestion that otitis-prone children have an impaired antibody response in the context of pneumococcal vaccination.
Research
Molecular surveillance of true nontypeable haemophilus influenzae: An evaluation of pcr screening assaysUnambiguous identification of nontypeable Haemophilus influenzae (NTHi) is not possible by conventional microbiology. Molecular characterisation of...
Research
Predictors of Disease Severity in Children Hospitalized for Pertussis during an EpidemicThis study aimed to determine factors associated with severe pertussis in hospitalized children during an epidemic using a novel pertussis severity scoring...